JPMorgan analyst Jessica Fye raised the firm’s price target on Jazz Pharmaceuticals to $202 from $190 and keeps an Overweight rating on the shares. The analyst rolled forward the price target to year-end 2025 from 2024. Coming out of Q2 earnings, the firm sees current share levels representing an attractive entry point. The business has better durability than the Street appreciates and the stock is trading at less than six-times the low end of 2024 guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target lowered to $154 from $160 at Baird
- Jazz Pharmaceuticals raises FY24 EPS view to $19.20-$20.30 from $18.15-$19.35
- Jazz Pharmaceuticals reports Q2 non-GAAP EPS $5.30, consensus $4.77
- Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
- Needham healthcare analysts hold analyst/industry conference call